Drug
Imiglucerase clinical trials
Also written Cerezyme and ISU302.
- studies test it
- 9
- open now
- 0
- in phase 3
- 3
- first study started
- 1997
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2001 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 3
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
ISU Abxis Co., Ltd. (4) · Genzyme, a Sanofi Company (3) · Sanofi (2)
Often tested with
Tested in the same studies.
Venglustat (1) · Abcertin (1)
Studies
Open first, then newest update. How each study uses imiglucerase is read from its arms, and is right about nine times in ten.
Testing it · 9
- Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionActive, not recruitingPhase 2Genzyme, a Sanofi CompanyNCT02843035Written as imiglucerase
- Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3CompletedPhase 3SanofiNCT03485677Written as Imiglucerase GZ437843
- Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type ⅢCompletedPhase 4SanofiNCT04656600Written as Cerezyme® / Imiglucerase
- A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy VolunteersCompletedPhase 1ISU Abxis Co., Ltd.NCT04787887Written as EU-sourced Cerezyme
- Phase III Study of ISU302 in Patients With Type 1 Gaucher DiseaseCompletedPhase 3ISU Abxis Co., Ltd.NCT02770625Written as ISU302
- The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher DiseaseWithdrawnPhase 3ISU Abxis Co., Ltd.NCT01161914Written as Cerezyme®
- Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT00364858Written as Cerezyme
- A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.CompletedPhase 4Genzyme, a Sanofi CompanyNCT00365131Written as Cerezyme (imiglucerase for injection)
- A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy VolunteersCompletedPhase 1ISU Abxis Co., Ltd.NCT01881633Written as ISU302
As the comparator · 3 — what is tested is compared with imiglucerase
- Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Active, not recruitingPhase 3SanofiNCT05222906Written as imiglucerase
- Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher DiseaseCompletedPhase 3ShireNCT00553631Written as imiglucerase
- A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)CompletedPhase 3Genzyme, a Sanofi CompanyNCT00943111Written as Imiglucerase
Codes
What other systems call imiglucerase · ClinicalTrials.gg INT003814
- MeSH (NLM) C090568imigluceraseConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q6U6J48BWYIMIGLUCERASEConfirmed FDA, NLM, Wikidata
- RxNorm 84959Confirmed FDA, Wikidata
- Wikidata Q2620206imigluceraseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65896ImigluceraseOne source FDA
- DrugBank DB00053One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C090568 | imiglucerase | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q6U6J48BWY | IMIGLUCERASE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 84959 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2620206 | imiglucerase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65896 | Imiglucerase | One source FDA |
| DrugBank | DB00053 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.